0000000001089788

AUTHOR

L Cortesi

showing 2 related works from this author

Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Itali…

2022

Constitutional BRCA1/BRCA2 pathogenic or likely pathogenic variants (PVs) are associated with an increased risk for developing breast and ovarian cancers. Current evidence indicates that BRCA1/2 PVs are also associated with pancreatic cancer, and that BRCA2 PVs are associated with prostate cancer risk. The identification of carriers of constitutional PVs in the BRCA1/2 genes allows the implementation of individual and family prevention pathways, through validated screening programs and risk-reducing strategies. According to the relevant and increasing therapeutic predictive implications, the inclusion of BRCA testing in the routine management of patients with breast, ovarian, pancreatic and…

Societies ScientificMaleOvarian NeoplasmsCancer Researchgenetic counselingBRCABRCA testing; BRCA-related cancer; BRCA1; BRCA2; PARP inhibitors; genetic counseling; pancreatic ductal adenocarcinomaProstatic Neoplasmspancreatic ductal adenocarcinomaScientificSettore MED/03 - GENETICA MEDICABRCA testing; BRCA-related cancer; BRCA1; BRCA2; PARP inhibitors; genetic counseling; pancreatic ductal adenocarcinoma; Female; Humans; Italy; Male; Societies Scientific; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic NeoplasmsBRCA1BRCA2BRCA-related cancerPancreatic NeoplasmsBRCA testingPARP inhibitorOncologyItalyHumansFemaleSocietiesPARP inhibitors
researchProduct

Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistr…

2017

BACKGROUND: Older patients are prone to multimorbidity and polypharmacy, with an inherent risk of adverse events and drug interactions. To the best of our knowledge, available information on the appropriateness of lipid-lowering treatment is extremely limited. AIM: The aim of the present study was to quantify and characterize lipid-lowering drug use in a population of complex in-hospital older patients. METHODS: We analyzed data from 87 units of internal medicine or geriatric medicine in the REPOSI (Registro Politerapie della Società Italiana di Medicina Interna) study, with reference to the 2010 and 2012 patient cohorts. Lipid-lowering drug use was closely correlated with the clinical prof…

Malemedicine.medical_specialtyLogistic ModelLipid-Lowering AgentsPopulationSocio-culturaleOlder Hospitalized Patients030204 cardiovascular system & hematologyGeriatrics and Gerontology; Pharmacology (medical)03 medical and health sciences0302 clinical medicineInternal medicine80 and overPrevalencemedicineHumansPharmacology (medical)030212 general & internal medicineMedical prescriptionIntensive care medicineOmega 3 fatty acideducationAdverse effectAgedHypolipidemic AgentsAged 80 and overPolypharmacyGeriatricseducation.field_of_studyHypolipidemic Agentbusiness.industryGeriatrics and Gerontology Pharmacology (medical)HospitalizationLogistic ModelsCohortPolypharmacyAged; Aged 80 and over; Female; Hospitalization; Humans; Hypolipidemic Agents; Logistic Models; Male; Polypharmacy; Prevalence; Geriatrics and Gerontology; Pharmacology (medical)FemaleGeriatrics and GerontologybusinessAged; Aged 80 and over; Female; Hospitalization; Humans; Hypolipidemic Agents; Logistic Models; Male; Polypharmacy; PrevalenceHumanCohort study
researchProduct